TWEAK levels in psoriatic patients treated with narrowband ultraviolet B and methotrexate

Background Psoriasis is an autoimmune disease which has an effect on the joints and skin. Tumor Necrosis Factor‐Like Weak Inducer of Apoptosis (TWEAK) is a multi‐functional cytokine which regulates the cellular processes and has been related to a variation of conditions. Objectives To measure the le...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cosmetic dermatology 2024-05, Vol.23 (5), p.1905-1911
Main Authors: Hegazy, Eisa Mohamed, El Taieb, Moustafa A., Ibrahim, Hassan Mohamed, Rageh, El‐Hassan M., Ahmed, Nour Mohammed, Ibrahim, Ahmed K., Younis, Ali Mohamed, Ali, Mahmoud Ahmed
Format: Article
Language:English
Subjects:
Adult
Combined Modality Therapy
Cytokine TWEAK - blood
Dermatologic Agents - administration & dosage
Dermatologic Agents - therapeutic use
Female
Humans
Male
methotrexate
Methotrexate - administration & dosage
Methotrexate - therapeutic use
Middle Aged
NB‐UVB
psoriasis
Psoriasis - blood
Psoriasis - diagnosis
Psoriasis - drug therapy
Psoriasis - radiotherapy
Psoriasis - therapy
Severity of Illness Index
Treatment Outcome
TWEAK
Ultraviolet Therapy - methods
Young Adult
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Psoriasis is an autoimmune disease which has an effect on the joints and skin. Tumor Necrosis Factor‐Like Weak Inducer of Apoptosis (TWEAK) is a multi‐functional cytokine which regulates the cellular processes and has been related to a variation of conditions. Objectives To measure the level of serum TWEAK in psoriatic diseased persons and its relationship to the PASI score pre‐ and post‐therapy with narrowband ultraviolet B phototherapy (NB‐UVB) and methotrexate (MTX). Methods This randomized controlled trial was conducted on 40 patients and 20 healthy persons as controls. Patient Group was randomly subdivided to two groups. The 1st group consisted of 20 patients who received NB‐UVB treatment. The 2nd group included 20 MTX‐treated candidates. Blood samples were drawn from patients in order to detect serum TWEAK levels using ELISA. The research was registered on Clinical Trials Registration: RCT approval numbers: NCT0481191. Results The mean PASI score percent improvement after 12 weeks of treatment was higher in the MTX group (90%) than NB‐UVB group (60%). The serum TWEAK level at baseline was 60.47 ± 12.6 pg/mL in NB‐UVB group and 54.69 ± 21.7 pg/mL in MTX group which reduced to 24.93 ± 17.6 pg/mL and 32.13 ± 23.6 pg/mL, respectively (p 
ISSN:1473-2130
1473-2165
DOI:10.1111/jocd.16215